ASBP
Aspire BioPharma, Inc.
NASDAQ: ASBP · HEALTHCARE · BIOTECHNOLOGY
$5.17
-11.74% today
Updated 2026-06-05
Market cap
$7.80M
P/E ratio
—
P/S ratio
225.65x
EPS (TTM)
$-7.09
Dividend yield
—
52W range
$3 – $1,050
Volume
16.3M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.3
Quality
B+4.5
Profitability
C5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
—
—
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.13x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-3.04M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $6202.00 | $34560.00 |
| Net income | $3.34M | $4.46M | $-12.54M | $-24.48M | $-3.22M |
| EPS | — | — | — | — | $-7.09 |
| Free cash flow | $-1.41M | $-653110.00 | $-265186.00 | $-4.92M | $-3.04M |
| Profit margin | — | — | — | -394,725.06% | — |
Peer comparison
Smart narrative
Aspire BioPharma, Inc. trades at $5.17. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. TTM revenue stands at $34560.00.
Frequently asked questions
What is Aspire BioPharma, Inc.'s stock price?
Aspire BioPharma, Inc. (ASBP) trades at $5.17, on a P/S of 225.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Aspire BioPharma, Inc. overvalued?
Aspire BioPharma, Inc. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is Aspire BioPharma, Inc.'s revenue?
Aspire BioPharma, Inc.'s trailing twelve-month revenue is $34560.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio225.65x
ROE-304.06%
Beta0.21
50D MA$2.21
200D MA$6.71
Shares out0.00B
Float0.00B
Short ratio—
Avg volume16.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—